论文部分内容阅读
目的 对比 IVP方案与 CAP方案治疗老年晚期非小细胞肺癌的临床疗效、生存期及毒副反应。方法 统计分析用 IVP(异环磷酰胺 ,鬼臼乙叉甙 ,顺铂 )方案及 CAP(环磷酰胺 ,阿霉素 ,顺铂 )方案治疗 1 1 5例老年晚期非小细胞肺癌病例的临床资料。结果 IVP组有效率为 58.6% ,其中完全缓解 5例 ,中位生存时间 1 1个月 ,1年生存率 31 % ;CAP组有效率为 2 9.8% ,中位生存时间 6.5个月 ,1年生存率 1 4 %。毒副反应主要为骨髓抑制 ,消化道反应及脱发。结论 IVP方案治疗老年晚期非小细胞肺癌疗效优于 CAP方案 ,毒副反应轻 ,值得作为一线治疗方案进一步推广应用。
Objective To compare the clinical efficacy, survival time and toxic and side effects of IVP and CAP in elderly patients with advanced non-small cell lung cancer. Methods Statistical analysis was performed using the IVP (ifosfamide, etoposide, cisplatin) and CAP (cyclophosphamide, doxorubicin, cisplatin) regimens in the treatment of 115 elderly patients with advanced non-small cell lung cancer. data. Results The effective rate in the IVP group was 58.6%, including 5 complete remissions, a median survival time of 11 months, a 1-year survival rate of 31%, a CAP group effective rate of 29.8%, a median survival time of 6.5 months, and 1 year The survival rate is 14%. The toxic side effects were mainly myelosuppression, gastrointestinal reactions and hair loss. Conclusion The IVP regimen is superior to the CAP regimen in the treatment of elderly patients with advanced non-small cell lung cancer. The toxicity of the IVP regimen is mild and it is worthy of further promotion as a first-line treatment regimen.